MicroRNA-155 and microRNA-196b: Promising biomarkers in hepatitis C virus infection?

Reviews in Medical Virology

Volumn 24, Issue 3, 2014, Pages 169-185

  Kałuzna, Ewelina Maria ^a  

^a INSTITUTE OF HUMAN GENETICS   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MIRN155 MICRORNA, HUMAN; MIRN196 MICRORNA, HUMAN;

CARCINOMA, HEPATOCELLULAR; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; HEPATITIS C; HOST PATHOGEN INTERACTION; HUMAN; LIVER CELL; LIVER NEOPLASMS; METABOLISM; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER NEOPLASMS; MICRORNAS; VIRUS REPLICATION;

EID: 84898822284     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1785     Document Type: Review

References (103)

1. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-526.
2. Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46: 48-57.
3. Corbeau P. Interfernig RNA and HIV: reciprocal interferences. PLoS Pathogen 2008; 4:e1000162. DOI: 10.1371/journal.ppat.1000162
4. Grassmann R, Jeang KT. The role of microRNAs in mammalian virus infection. Biochimica et Biophysica Acta 2008; 1779: 706-711. DOI: 10.1016/j.bbagrm.2008.05.005
5. Cho W. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert opinion on therapeutic target. 2012; 16: 747-759.
6. http://www.mirbase.org/ (7 June 2013)
7. Alvarez-Garcia I, Miska EA. MicroRNA functions in animals development and human disease. Development 2005; 135: 4635-4662.
8. Baltimore D, Boldyn MP, O'Connell RM, et al. MicroRNAs: new regulators of immune cell development and function. Nature Immunology 2008; 9: 839-845. DOI: 10.1038/ni.f.209
9. Carrisimi C, Fulci V, Macino G. MicroRNAs: novel regulators of immunity. Autoimmunity Reviews 2009; 8: 520-524. DOI: 10.1016/j.autrev.2009.01.008
10. Li SC, Tang P, Lin WC. Intronic micro-RNA: discovery and biological implications. DNA and Cell Biology 2007; 26: 196-207.
11. Gregory RI, Yan K, Amuthan G, et al. The microprocessor complex mediates the genesis of microRNAs. Nature 2004; 432: 235-40. DOI: 10.1523/JNEUROSCI.5065-07.2008
12. Kim VN. MicroRNA precursor in motion: exportin 5 mediates their nuclear export. Trends in Cell Biology 2004; 14: 156-159. DOI: 10.1016/j.tcb.2004.02.006
13. Zhang H, Kolb FA, Jaskiewicz L, et al. Single processing center models for human dicer and bacterial RNase III. Cell 2004; 118: 57-68.
14. Ouellet DL, Perron MP, Gobeli LA, et al. MicroRNAs is gene regulation: when the smallest governs it All. Journal of Biomedicine & Biotechnology (on-line) 2006; 2006 1-20.
15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 2004; 116: 281-297.
16. Lewis BP, Burge CB, Bartel DP. Conserved seed pai ring, often flanked by adenosines, indicates that thousands of human genes are microRNA target. Cell 2005; 120: 15-20.
17. Liu J, Valencia-Sanchez MA, Hannon GJ, et al. MicroRNA-dependent localization of targeted MiRNAs to mammalian P-bodies. Nature Cell Biology 2005; 7: 719-723.
18. Guo HO, Ingolia NT, Weissman JS, et al. Mammalian microRNA predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840. DOI: 10.1038/nature09267
19. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 13556-13561. DOI: 10.1073/pnas.0803055105
20. Ji J, Wang XW. New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biology and Therapy 2009; 8: 1686-1693.
21. Gantier MP. New perspectives in microRNA regulation of innate immunity. Journal of Interferon Research 2010; 30: 283-289. DOI: 10.1089/jir.2010.0037
22. Tili E, Michaille JJ, Cimino A, et al. Modulation of miR-155 and miR-125 levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. Journal of Immunology 2007; 179: 5082-5089.
23. O'Connell RM, Rao DS, Baltimore D. MicroRNA regulation in inflammatory responses. Annual Review of Immunology 2012; 30: 295-312. DOI: 10.1146/annurev-immunol-020711-075013
24. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Critical Reviews in Oncology/Hematology 2011; 107: 265-269. DOI: 10.1016/j.critrevonc.2010.11.004
25. Carreno V, Pardo M, Lopez-Alcorocho JM, et al. Detection of hepatitis C virus RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. Journal of Infectious Diseases 2006; 194: 53-60.
26. Pham TN, King D, Macparland SA, et al. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008; 134: 812-822. DOI: 10.1053/j.gastro.2007.12.011
27. Wei L, Gong X, Martinez O, et al. Differential expression and functions of microRNAs in liver transplantation and potential use as non-invasive biomarkers. Transplant Immunology 2013. in press: DOI: 10.1016/j.trim.2013.08.005
28. Pol S, Vallet-Pichard A, Corouge M, et al. Hepatitis C: epidemiology, diagnosis, natural history and therapy. Contributions to Nephrology 2012; 176: 1-9. DOI: 10.1159/000332374
29. Rosen HR. Clinical practice. Chronic hepatitis C infection. New England Journal of Medicine 2011; 364: 2429-2438. DOI: 10.1056/NEJMcp1006613
30. Poordad F, Dieterich D. Treating hepatitis type C: current standard of care and emerging direct-acting antiviral agents. Journal of Viral Hepatitis 2012; 19: 449-464. DOI: 10.1111/j.1365-2893.2012.01617.x
31. Brojer E. Badania serologicznych i molekularnych markerów HCV u dawców krwi w Polsce. Przeg Epidemiol 2005; 59: 511-517.
32. Craxi A, Pawlotsky JM, Wedemeyer H, et al. EASL clinical practice guidelines: management of hepatitis C virus infection. Journal of Hepatology 2011; 55: 245-264. DOI: 10.1016/j.jhep.2011.02.023
33. Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annual Review of Pharmacology and Toxicology 2013; 53: 427-449. DOI: 10.1146/annurev-pharmtox-011112-140254
34. Scangolari C, ZingaRiello P, Vecchiet J, et al. Differential expression of interefon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha. Journal of Virology 2010; 7: 311-320. DOI: 10.1186/1743-422X-7-311
35. Shimakami T, Yamane D, Welsh C, Hensley L, Jangra RK, Lemon SM. Base pairing between hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome stabilization and production of infectious virus. Journal of Virology 2012; 86: 7372-7383. DOI: 10.1128/JVI.00513-12
36. Jopling CL. Regulation of hepatitis C virus by microRNA-122. Biochemical Society Transactions 2008; 2008; 36: 1220-1223. DOI: 10.1042/BST0361220
37. Hsu SH, Wang B, Kota J, et al. Essential metabolic anti-inflammatory, and anti-tumorogenic functions of miR-122 in liver. Journal of Clinical Investigation 2012; 122: 2871-2883. DOI: 10.1172/JCI63539
38. Niepmann M. Activation of hepatitis C virus translation by a liver-specific microRNA. Cell Cycle 2009; 8: 1473-1477.
39. Shimakami T, Yamane D, Jangra RK, et al. Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 an regulation of hepatitis C virus RNA by an Ago2-miR-122 complex. Proceedings of the National Academy of Sciences 2012; 109: 941-946.
40. McFarland AP, Horner SM, Jarret A, et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nature Immunology 2014; 15: 72-79. DOI: 10.1038/ni.2758
41. Faraoni I, Antonetti FR, Cardone J, et al. miR-155 gene: a typical multifunction microRNA. Biochimica et Biophysica Acta 2009; 497-505. DOI: 10.1016/j.bbadis.2009.02.013
42. Tam W, Ben-Yehuda D, Hayward WS. Bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA. Molecular and Cellular Biology 1997; 17: 1490-1502.
43. Bala S, Marcos M, Kodys K, et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor alpha (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. Journal of Biological Chemistry 2011; 286: 1436-1444.
44. O'Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 1604-1609.
45. Cheung ST, So EY, Chang D, et al. Interleukin-10 inhibits lipopolysaccharide induced miR-155 precursor stability and maturation. PLoS One 2013; 8: e71336. DOI: 10.1371/journal.pone.0071336
46. Grek M, Piekarska A, Bartkowiak J, et al. Coordinated increase of miRNA-155 and miRNA196b expression correlates with detection of the antigenomic strand of hepatitis C virus in peripheral blood mononuclear cells. International Journal of Molecular Medicine 2011; 28: 875-880. DOI: 10.3892/ijmm.2011.748
47. Bala S, Tilhaun Y, Taha O, et al. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. Journal of Translational Medicine 2012; 10: 151-161. DOI: 10.1186/1479-5876-10-151
48. Zhang Y, Wei W, Cheng N, et al. Hepatitis C virus induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012; 56: 1631-1640. DOI: 10.1002/hep.25849
49. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 3627-3632.
50. Rai D, Karanti S, Jung I, et al. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genetics and Cytogenetics 2008; 181: 8-15. DOI: 10.1016/j.cancergencyto.2007.10.008
51. Dolganiuc A, Oak S, Kodys K, et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127: 1513-1524.
52. Waggoner SN, Hail CH, Hahn YS. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. Journal of Leukocyte Biology 2007; 82: 1407-1419.
53. Sidorkiewicz M, Grek M, Jozwiak B, et al. Expression of microRNA-155 precursor in peripheral blood mononuclear cells from hepatitis C patients after antiviral treatment. Acta Virologica 2010; 54: 75-78.
54. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26: 4442-4452.
55. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 19075-19080
56. Wang XW, Heegaard NH, Qrum H. MicroRNAs in liver disease. Gastroenterology 2012; 142: 1431-1443.
57. Han Z, Chen H, Fan J, et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. Journal of Cancer Research and Clinical Oncology 2012; 138: 153-161. DOI: 10.1007/s00432-011-1076-z
58. Tili E, Croce CM, Michaille JJ. miR-155: on the crosstalk between inflammation and cancer. International Reviews of Immunology 2009; 28: 264-284. DOI: 10.1080/08830180903093796
59. Yan XL, Jia YL, Chen L, et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology 2013; 57: 2274-2286.
60. Xie Q, Chen X, Lu F, et al. Aberrant expression of microRNA-155 may accelerate cell proliferation by targeting sex-determining region Y box6 in hepatocellular carcinoma. Cancer 2012; 118: 2431-2442. DOI: 10.1002/cncr.26566
61. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circulation Research 2010; 107: 677-684. DOI: 10.1161/CIRCRESAHA.109.215566
62. Lagos-Quintana M, Rauhut R, Meyer J, et al. New microRNAs from mouse and human. RNA 2003; 9: 175-179.
63. Pedersen IM, Cheng G, Wieland S, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449: 919-922.
64. Shan Y, Zheng J, Lambrecht RW, et al. Reciprocal effects of micro-RNA-122 of expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gatroenterology 2007; 133: 1166-1174
65. Zhu Z, Wilson AT, Mathahs MM, et al. Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 2008; 48: 1430-1439. DOI: 10.1002/hep.22491
66. Hou W, Tian Q, Zheng J, et al. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C virus proteins. Hepatology 2009; 51: 1-11. DOI: 10.1002/hep.23401
67. Chen C, Zhang Y, Zhang L, et al. MicroRNA-196: critical roles and clinical applications in development and cancer. Journal of Cellular and Molecular Medicine 2011; 15: 14-23. DOI: 10.1111/j.1582-4934.2010.01219.x
68. Szafranska AE, Doleshal M, Edmunds HS, et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clinical Chemistry 2008; 54: 1716-1724. DOI: 10.1373/clinchem.2008.109603
69. Hui AB, Shi W, Boutros PC, et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Laboratory Investigation 2009; 89: 597-606. DOI: 10.1038/labinvest.2009.12
70. Popovic R, Riesbeck LE, Velu CS, et al. Regulation of miR-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 2009; 113: 3314-3322. DOI: 10.1182/blood-2008-04-154310
71. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prevention Research 2009; 2: 807-813. DOI: 10.1158/1940-6207.CAPR-09-0094
72. Schotte D, Chau JC, Sylvester G, et al. Identification of new microRNA genes an aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 2009; 23: 313-322. DOI: 10.1038/leu.2008.286
73. Li Y, Zhang M, Chen H. Ratio of miR-196b to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. Cancer Research 2010; 70: 7894-7904. DOI: 10.1158/0008-5472.CAN-10-1675
74. Shen J, Wang S, Zhang UJ, et al. Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma. Epigenetics 2012; 7: 1230-1237. DOI: 10.4161/epi.22140
75. Bihrer V, Waidmann O, Friedrich-Rust M, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011; 6: e26971. DOI: 10.1371/journal.pone.0026971
76. Marquez RT, Bandyopadhyhy S, Wendlandt EB, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Laboratory Investigation 2010; 90: 1727-1736. DOI: 10.1038/labinvest.2010.126
77. Cermelli S, Ruggieri A, Marrero JA, et al. Ciculating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6: e23937. DOI: 10.1371/journal.pone.0023937
78. Morita K, Taketomii A, Shirabe K, et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver International 2011; 31: 474-484. DOI: 10.1111/j.1478-3231.2010.02433.x
79. Murakami Y, Aly HH, Tajima A, et al. Regulation of the hepatitis C virus genome replication by miR-199a. Journal of Hepatology 2009; 50: 453-460. DOI: 10.1016/j.jhep.2008.06.010
80. Murakami Y, Toyoda H, Tanaka M, et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 2011; 6: e16081. DOI: 10.1371/journal.pone.0016081
81. Ura S, Honda M, Yamashita T, et al. Differential MicroRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49: 1098-1112. DOI: 10.1002/hep.22749
82. Peng X, Li Y, Walters KA, et al. Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics 2009; 10: 373-393. DOI: 10.1186/1471-2164-10-373
83. Li Z, Huang H, Chen P, et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nature Communications 2012; 3: 688-712. DOI: 10.1038/ncomms1681
84. Ishida H, Tatsumi T, Hosui A, et al. Alterations in microRNA expression profile in HCV infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/AKT pathway. Biochemical and Biophysical Research Communications 2011; 412: 92-97. DOI: 10.1016/j.bbrc.2011.07.049
85. Abdalla MA, Haj-Ahmad Y. Promising candidate urinary microRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer 2012; 3: 19-31. DOI: 10.7150/jca.3.19
86. Xiong Y, Fang J, Yun J, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-845. DOI: 10.1002/hep.23380
87. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3a and 3b. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 15805-15810
88. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. Journal of Clinical Oncology 2011; 29: 4781-4788. DOI: 10.1200/JCO.2011.38.2697
89. Qi P, Cheng SQ, Wang H, et al. Serum microRNAs as a biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011; 6: e28486. DOI: 10.1371/journal.pone.0028486
90. Bandyopadhyay S, Friedman RC, Marquez RT, et al. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. JID 2011; 203: 1753-1762. DOI: 10.1093/infdis/jir186
91. Yang T, Liang Y, Lin Q, et al. MiR-29 mediates TGFbeta1-induced extracellular matrix synthesis through activation of PI3K-AKT pathway in human lung fibroblast. Journal of Cellular Biochemistry 2013; 114: 1336-1342. DOI: 10.1002/jcb.24474
92. Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005; 309: 577-1581.
93. Roberts A, Lewis P, Jopling C. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Research 2011; 39. DOI: 10.1093/nar/gkr426
94. Zheng F, Liao YJ, Cai MY, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012; 61: 278-289. DOI: 10.1136/gut.2011.239145
95. Zeng B, Li Z, Chen R, et al. Epigenetic regulation of miR-124 by hepatitis C virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3. FEBS Letters 2012; 586: 3271-3278. DOI: 10.1016/j.febslet.2012.06.049
96. Cheng JC, Yeh YJ, Tseng CP, et al. Let-7b is a novel regulator of hepatitis C virus replication. Cellular and Molecular Life Sciences 2012; 69: 2621-2633. DOI: 10.1007/s00018-012-0940-6
97. Yin Q, McBride J, Fewell C, et al. MicroRNA-155 is Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. Journal of Virology 2008; 82: 5295-5306. DOI: 10.1128/JVI.02380-07
98. Neilsen PM, Noll JE, Mattiske S, et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 2013; 32: 2992-3000. DOI: 10.1038/onc.2012.305
99. O'Connel RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. Journal of Experimental Medicine 2008; 205: 585-594. DOI: 10.1084/jem.20072108.
100. Gironella M, Seux M, Xie MJ, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by mir-155, and its restoration inhibits pancreatic tumor development. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 16170-16175.
101. Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 2735-2740.
102. Abe W, Nasu K, Nakada C, et al. miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells. Human Reproduction 2013; 0: 1-12. DOI: 10.1093/humrep/des446.
103. Vigorito E, Perks KL, Abreu-Goodger C, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007; 27: 847-859.